A phase II randomized study to investigate Espranor (rapidly dissolving oral lyophilisate formulation of buprenorphine)

Trial Profile

A phase II randomized study to investigate Espranor (rapidly dissolving oral lyophilisate formulation of buprenorphine)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 May 2017

At a glance

  • Drugs Buprenorphine (Primary) ; Buprenorphine
  • Indications Opioid abuse
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 May 2017 New trial record
    • 05 May 2017 According to a Martindale Pharma media release, results from this trial have been published in European Addiction Research.
    • 05 May 2017 Results published in a Martindale Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top